Screener
Maravai LifeSciences Holdings, Inc. MRVI Cygnus — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001823239-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | $51,442 | $47,397 | $117,279 | $94,247 |
| Cost of revenue | 30,792 | 39,629 | 62,928 | 78,754 |
| Gross profit | 20,650 | 7,768 | 54,351 | 15,493 |
| Operating expenses: | ||||
| Selling, general and administrative | 32,070 | 38,715 | 61,162 | 78,279 |
| Research and development | 3,702 | 4,882 | 7,591 | 9,770 |
| Goodwill impairment | — | 30,449 | — | 42,884 |
| Restructuring | (33) | — | 2,845 | — |
Item 1. Financial Statements
FAQ
- What is Maravai LifeSciences Holdings, Inc.'s cygnus — revenue?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported cygnus — revenue of $16.77M in Q2 2026.
- How has Maravai LifeSciences Holdings, Inc.'s cygnus — revenue changed year-over-year?
- Maravai LifeSciences Holdings, Inc.'s cygnus — revenue increased by 2.8% year-over-year, from $16.31M to $16.77M.
- What is the long-term trend for Maravai LifeSciences Holdings, Inc.'s cygnus — revenue?
- Over 4 years (2021 to 2025), Maravai LifeSciences Holdings, Inc.'s cygnus — revenue has grown at a -0.9% compound annual growth rate (CAGR), from $68.42M to $65.96M.
- What does cygnus — revenue mean?
- Represents the total gross income generated by the Biologics Safety Testing business segment through the sale of products and services. This metric reflects the market demand for safety testing solutions used in the development of drug therapies and vaccines. It serves as a primary indicator of the segment's commercial performance and market penetration.
Ask your AI about Maravai LifeSciences Holdings, Inc.'s cygnus — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude